Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Circ Cardiovasc Interv. 2013 Feb;6(1):37-43. doi: 10.1161/CIRCINTERVENTIONS.112.974493. Epub 2013 Jan 15.
Contrast-induced acute kidney injury (CI-AKI) has been associated with mortality, although it has been suggested this association may be attributable to confounding. We performed a systematic review and meta-analysis to characterize the associations between CI-AKI and subsequent clinical outcomes.
We identified studies using MEDLINE (1950 to June 2011) and Embase (1980 to June 2011), manual bibliographic searches, and contact with experts. We included observational studies that characterized outcomes among patients with and without AKI (based on changes in serum creatinine) after coronary angiography. Eligible studies reported at least 1 of mortality, cardiovascular events, end-stage renal disease, or length of hospital stay. Thirty-nine observational studies met inclusion criteria. Of 34 studies reporting mortality (including 139 603 participants), 33 reported an increased risk of death in those with CI-AKI, although the effect size varied between studies (I(2)=93.5%). Between-study heterogeneity was partially explained by whether adjustment for confounding features was performed (11 studies without adjustment; pooled crude risk ratio, 8.19; 95% confidence interval, 4.30-15.60; I(2)=77.3% versus 23 studies with adjustment; pooled adjusted risk ratio, 2.39; 95% confidence interval, 1.98-2.90; I(2)=88.3%). CI-AKI was consistently associated with an increased risk of cardiovascular events in 14 studies, end-stage renal disease in 3 studies, and prolonged hospitalization in 11 studies.
CI-AKI is associated with an increased risk of mortality, cardiovascular events, renal failure, and prolonged hospitalization. However, the association between CI-AKI and mortality is strongly confounded by baseline clinical characteristics that simultaneously predispose to both kidney injury and mortality, and the risk attributable to CI-AKI is much lower than that reported from unadjusted studies.
对比剂诱导的急性肾损伤(CI-AKI)与死亡率相关,尽管有人提出这种关联可能归因于混杂因素。我们进行了系统评价和荟萃分析,以描述 CI-AKI 与随后的临床结局之间的关系。
我们使用 MEDLINE(1950 年至 2011 年 6 月)和 Embase(1980 年至 2011 年 6 月)、手工文献检索以及与专家联系来确定研究。我们纳入了描述接受冠状动脉造影后有无 AKI(基于血清肌酐变化)患者结局的观察性研究。合格研究报告了至少 1 项死亡率、心血管事件、终末期肾病或住院时间的结果。39 项观察性研究符合纳入标准。在 34 项报告死亡率的研究中(包括 139603 名参与者),有 33 项研究表明 CI-AKI 患者的死亡风险增加,尽管研究之间的效应大小存在差异(I²=93.5%)。异质性部分可以通过是否进行混杂因素调整来解释(11 项未调整的研究;汇总粗风险比为 8.19;95%置信区间,4.30-15.60;I²=77.3%,而 23 项调整的研究;汇总调整后的风险比为 2.39;95%置信区间,1.98-2.90;I²=88.3%)。CI-AKI 与 14 项研究中的心血管事件风险增加、3 项研究中的终末期肾病和 11 项研究中的住院时间延长始终相关。
CI-AKI 与死亡率、心血管事件、肾衰竭和住院时间延长的风险增加相关。然而,CI-AKI 与死亡率之间的关联受到基线临床特征的强烈混杂,这些特征同时导致肾脏损伤和死亡率增加,而归因于 CI-AKI 的风险远低于未经调整的研究报告的风险。